YYAI vs PRCT

For growth investors, AiRWA Inc.

(YYAI) is the stronger pick with 52. 6% revenue growth year-over-year, versus 37. 2% for PROCEPT BioRobotics Corporation (PRCT). AiRWA Inc. (YYAI) offers the better valuation at 0. 1x trailing P/E, making it the more compelling value choice. Analysts rate PROCEPT BioRobotics Corporation (PRCT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, PROCEPT BioRobotics Corporation (PRCT) delivered a total return of -39.

4%, compared to -100. 0% for AiRWA Inc. (YYAI). Over 10 years, the gap is even starker: PRCT returned -39. 4% versus YYAI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), PROCEPT BioRobotics Corporation (PRCT) is the lower-risk stock at 1.

14β versus AiRWA Inc. 's 3. 10β — meaning YYAI is approximately 171% more volatile than PRCT relative to the S&P 500. On balance sheet safety, AiRWA Inc. (YYAI) carries a lower debt/equity ratio of 3% versus 14% for PROCEPT BioRobotics Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AiRWA Inc.

(YYAI) is pulling ahead at 52. 6% versus 37. 2% for PROCEPT BioRobotics Corporation (PRCT). On earnings-per-share growth, the picture is similar: AiRWA Inc. grew EPS 100. 8% year-over-year, compared to 1. 7% for PROCEPT BioRobotics Corporation. Over a 3-year CAGR, PRCT leads at 60. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AiRWA Inc.

(YYAI) is the more profitable company, earning 27. 2% net margin versus -31. 0% for PROCEPT BioRobotics Corporation — meaning it keeps 27. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: YYAI leads at 51. 3% versus -33. 7% for PRCT. At the gross margin level — before operating expenses — YYAI leads at 76. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, PROCEPT BioRobotics Corporation (PRCT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

14)). AiRWA Inc. (YYAI) carries a higher beta of 3. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRCT: -39. 4%, YYAI: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (YYAI (Consumer Cyclical) and PRCT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.